论文部分内容阅读
[目的]探讨奥沙利铂联合希罗达治疗晚期及复发性胃癌的临床疗效及副作用。[方法]选择晚期及复发性胃癌46例,d 1给予奥沙利铂130 mg/m2;d 1~14,口服希罗达化疗2 000 mg/m2,分两次服用,早、晚饭后半小时各1次。每3周为1周期,每位患者至少接受两个周期的化疗。[结果]所有患者共完成178个周期化疗,平均3.87个周期(2~6)。化疗完成后,达到CR的有10例,达到PR的有19例,达到SD的有10例,达到PD的有7例,有效率为63.04%。中位生存期为13.2月,中位缓解期8.1个月。患者的毒副反应均较轻,不良反应主要为骨髓抑制、神经毒性、消化道反应及手足综合征。[结论]采用奥沙利铂联合希罗达的联合治疗方案治疗晚期及复发性胃癌具有良好的疗效,毒副反应轻,值得临床推广。
[Objective] To investigate the clinical efficacy and side effects of oxaliplatin combined with Xeloda in the treatment of advanced and recurrent gastric cancer. [Methods] Forty-six patients with advanced and recurrent gastric cancer were enrolled. Patients were given oxaliplatin 130 mg / m 2 for d 1 to 14 000 mg / m 2 for oral administration of Xeloda 2 mg twice daily after breakfast and after dinner 1 hour each. Every 3 weeks for a cycle, each patient received at least two cycles of chemotherapy. [Results] All patients completed a total of 178 cycles of chemotherapy, an average of 3.87 cycles (2 to 6). After the completion of chemotherapy, there were 10 cases of CR, 19 cases of PR, 10 cases of SD and 7 cases of PD. The effective rate was 63.04%. The median survival time was 13.2 months, with a median response time of 8.1 months. Toxic side reactions in patients are lighter, the main adverse reactions are myelosuppression, neurotoxicity, gastrointestinal reactions and hand-foot syndrome. [Conclusion] The combination of oxaliplatin and Xeloda in the treatment of advanced and recurrent gastric cancer has good curative effect, light toxicity, and worthy of clinical promotion.